SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001694665-22-000043
Filing Date
2022-03-24
Accepted
2022-03-24 07:19:06
Documents
14
Period of Report
2022-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evlo-20220324.htm   iXBRL 8-K 35132
2 EX-99.1 exhibit9914qearningspr8-k.htm EX-99.1 98076
6 evelologo.jpg GRAPHIC 8150
  Complete submission text file 0001694665-22-000043.txt   298060

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evlo-20220324.xsd EX-101.SCH 1903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evlo-20220324_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evlo-20220324_pre.xml EX-101.PRE 13047
8 EXTRACTED XBRL INSTANCE DOCUMENT evlo-20220324_htm.xml XML 11252
Mailing Address 620 MEMORIAL DRIVE SUITE 200 WEST CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 200 WEST CAMBRIDGE MA 02139 617 870 8281
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

IRS No.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 22764688
SIC: 2834 Pharmaceutical Preparations